Nanosphere Inc.

 

NORTHBROOK, Ill., April 7, 2015 (GLOBE NEWSWIRE) -- Nanosphere, Inc. (Nasdaq:NSPH), a company enhancing medicine through targeted molecular diagnostics, announced today that a 20-to-1 reverse split of its common stock will be effective at 5:00 p.m. EDT on April 8, 2015, and commencing at the open of trading on Thursday, April 9, 2015, trading of the common stock will continue on the NASDAQ Capital Market on a reverse stock split-adjusted basis. The reverse stock split was approved by the company's stockholders at the special meeting of stockholders held today. The company's board of directors approved the implementation of a reverse stock split and determined the appropriate reverse stock split ratio to be 20-to-1.

At the effective time of the reverse stock split, every 20 shares of Nanosphere's issued and outstanding common stock will be converted into one newly issued and outstanding share of common stock, without any change in the par value per share.

The reverse stock split will reduce the number of shares of Nanosphere's outstanding common stock from approximately 117.2 million to approximately 5.9 million. Proportional adjustments will be made to Nanosphere's outstanding stock options, outstanding warrants, and equity-compensation plans. The number of authorized shares of the company's common stock will remain unchanged. Once the reverse stock split becomes effective, stockholders holding shares through a brokerage account will have their shares automatically adjusted to reflect the 20:1 reverse stock split. Existing stockholders holding common stock certificates will receive a letter of transmittal from the company's transfer agent, American Stock Transfer & Trust Company, LLC, with specific instructions regarding the exchange of shares. No fractional shares will be issued in connection with the reverse stock split. Any fractional shares resulting from the reverse stock split will be rounded up to the nearest whole share.

The company's common stock will continue to trade on the NASDAQ Capital Market under the symbol "NSPH." A new CUSIP number of 63009F204 has been assigned to the common stock in connection with the reverse stock split  

dann nur noch ca. 6 Millionen im Float. Der RS 20:1 war ja schon länger bekannt.  

Nanosphere Achieves Record Revenues of $4.7 Million for Second Quarter 2015
Published on August 11, 2015 at 4:42 AM
Nanosphere, Inc., a company enhancing medicine through targeted molecular diagnostics, today reported financial and operating results for the second quarter ended June 30, 2015.

Nanosphere achieved record revenues for the second quarter 2015, of $4.7 million compared to $2.7 million in the second quarter 2014. This 76% year-over-year revenue growth was driven by U.S. based microbiology laboratories' continued adoption of our Gram Positive (BCGP) and Gram Negative (BCGN) blood culture tests, which grew more than 87% over Q2 2014. The Company also confirmed full year revenue guidance for 2015 of $18-20 million.

"We are pleased to report another consecutive quarter of record revenue and gross profit improvement. This progress is driven by a clear focus on execution and continued adoption of our Verigene system and its expanding menu though our U.S. customer base. In addition, we continue to make significant progress on our next generation Verigene system and expect to start clinical trials by year end," said Michael McGarrity, Nanosphere's president and chief executive officer. "We are confident that our growth and competitive position in the market will continue to advance driven by our best in class performance, differentiated clinical and economic utility provided by our proprietary flex panel design, and continued productivity in our sales, cost reduction and development efforts."

Gross margins increased to 49% in the second quarter of 2015 from 38% in the second quarter of 2014, driven by consumable cost reductions, coupled with lower royalty expenses due to the expiration of certain agreements. Sales, general and administrative expenses in the second quarter of 2015 decreased to $5.6 million from $6.7 million in the prior year period, and research and development expenses increased to $4.5 million in the second quarter of 2015, as compared to $4.0 million in the second quarter of 2014 due to continued investment in new product development

Net loss for the second quarter of 2015 was $8.6 million, as compared to $10.0 million in the second quarter of 2014.

Cash at June 30, 2015 was $23.9 million, with $3 million of this being restricted cash. Cash used in operations at the quarter ended June 30, 2015 was $13.7 million, compared to $18.6 million for the same period in 2014 due to a lower net operating loss.

Conference Call & Webcast

Tuesday, August 11, 2015 @ 8:30am Eastern Time/5:30am Pacific Time
Domestic: 888-587-0615 FREE
International: 719-325-2393 FREE
Passcode: 9125831
Webcast: http://www.nanosphere.us/investors

Replays – Available through August 25, 2015
Domestic: 877-870-5176 FREE
International: 858-384-5517 FREE

Source: http://www.nanosphere.us/
 

Aktie fast noch auf Jahrestief. Jahreshoch bei 9 $. Mal schauen, was geht. Rechne mit zweistelligen Plus heute.